Last reviewed · How we verify
Flivas (NAFTOPIDIL)
At a glance
| Generic name | NAFTOPIDIL |
|---|---|
| Sponsor | Asahi Kasei |
| Drug class | naftopidil |
| Target | Alpha-1D adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Benign prostatic hyperplasia
Common side effects
Key clinical trials
- Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS (PHASE3)
- Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia (PHASE4)
- Medical Expulsive Therapy for Ureter Stone Using Naftopidil (PHASE3)
- The Effect of Naftopidil for the Double-J Stent Discomfort (PHASE3)
- The Safety/Tolerability and Pharmacokinetics (PKs) of Naftopidil in Korean Healthy Male Volunteers (PHASE1)
- Naftopidil 75mg for Improving Clearance of Urinary Stones (PHASE4)
- Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flivas CI brief — competitive landscape report
- Flivas updates RSS · CI watch RSS
- Asahi Kasei portfolio CI